Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2215/CJN.01580210 http://scihub22266oqcxt.onion/10.2215/CJN.01580210 20538833!2924417!20538833     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=20538833&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\20538833.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Clin+J+Am+Soc+Nephrol 2010 ; 5 (8): 1388-93 Nephropedia Template TP {{tp|p=20538833|t=2010. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk |pdf=|usr=}}{{20538833}} gab.com Text Effect of allopurinol in chronic kidney disease progression and cardiovascular risk JO: Clin J Am Soc Nephrol http://www.kidney.de/pget.php?&tw=1&pmid=20538833 #FOAvip BACKGROUND AND OBJECTIVES: Hyperuricemia is associated with hypertension, inflammation, renal disease progression, and cardiovascular disease. However, no data are available regarding the effect of allopurinol in patients with chronic kidney disease. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a prospective, randomized trial of 113 patients with estimated GFR (eGFR) <60 ml/min. Patients were randomly assigned to treatment with allopurinol 100 mg/d (n = 57) or to continue the usual therapy (n = 56). Clinical, biochemical, and inflammatory parameters were measured at baseline and at 6, 12, and 24 months of treatment. The objectives of study were: (1) renal disease progression; (2) cardiovascular events; and (3) hospitalizations of any causes. RESULTS: Serum uric acid and C-reactive protein levels were significantly decreased in subjects treated with allopurinol. In the control group, eGFR decreased 3.3 +/- 1.2 ml/min per 1.73 m(2), and in the allopurinol group, eGFR increased 1.3 +/- 1.3 ml/min per 1.73 m(2) after 24 months. Allopurinol treatment slowed down renal disease progression independently of age, gender, diabetes, C-reactive protein, albuminuria, and renin-angiotensin system blockers use. After a mean follow-up time of 23.4 +/- 7.8 months, 22 patients suffered a cardiovascular event. Diabetes mellitus, previous coronary heart disease, and C-reactive protein levels increased cardiovascular risk. Allopurinol treatment reduces risk of cardiovascular events in 71% compared with standard therapy. CONCLUSIONS: Allopurinol decreases C-reactive protein and slows down the progression of renal disease in patients with chronic kidney disease. In addition, allopurinol reduces cardiovascular and hospitalization risk in these subjects. Twit Text FOAVip Effect of allopurinol in chronic kidney disease progression and cardiovascular risk ????Clin J Am Soc Nephrol http://www.kidney.de/pget.php?&tw=1&pmid=20538833 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=20538833 #FOAvip English Wikipedia <ref>{{Cite pmid|20538833}}</ref> Effect of allopurinol in chronic kidney disease progression and cardiovascular risk #MMPMID20538833 Goicoechea M; de Vinuesa SG; Verdalles U; Ruiz-Caro C; Ampuero J; Rincon A; Arroyo D; Luno J Clin J Am Soc Nephrol 2010[Aug]; 5 (8): 1388-93 PMID20538833show ga BACKGROUND AND OBJECTIVES: Hyperuricemia is associated with hypertension, inflammation, renal disease progression, and cardiovascular disease. However, no data are available regarding the effect of allopurinol in patients with chronic kidney disease. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a prospective, randomized trial of 113 patients with estimated GFR (eGFR) <60 ml/min. Patients were randomly assigned to treatment with allopurinol 100 mg/d (n = 57) or to continue the usual therapy (n = 56). Clinical, biochemical, and inflammatory parameters were measured at baseline and at 6, 12, and 24 months of treatment. The objectives of study were: (1) renal disease progression; (2) cardiovascular events; and (3) hospitalizations of any causes. RESULTS: Serum uric acid and C-reactive protein levels were significantly decreased in subjects treated with allopurinol. In the control group, eGFR decreased 3.3 +/- 1.2 ml/min per 1.73 m(2), and in the allopurinol group, eGFR increased 1.3 +/- 1.3 ml/min per 1.73 m(2) after 24 months. Allopurinol treatment slowed down renal disease progression independently of age, gender, diabetes, C-reactive protein, albuminuria, and renin-angiotensin system blockers use. After a mean follow-up time of 23.4 +/- 7.8 months, 22 patients suffered a cardiovascular event. Diabetes mellitus, previous coronary heart disease, and C-reactive protein levels increased cardiovascular risk. Allopurinol treatment reduces risk of cardiovascular events in 71% compared with standard therapy. CONCLUSIONS: Allopurinol decreases C-reactive protein and slows down the progression of renal disease in patients with chronic kidney disease. In addition, allopurinol reduces cardiovascular and hospitalization risk in these subjects. |Aged[MESH] |Allopurinol/adverse effects/*therapeutic use[MESH] |Biomarkers/blood[MESH] |C-Reactive Protein/metabolism[MESH] |Cardiovascular Diseases/blood/etiology/*prevention & control[MESH] |Chi-Square Distribution[MESH] |Chronic Disease[MESH] |Disease Progression[MESH] |Glomerular Filtration Rate/drug effects[MESH] |Gout Suppressants/adverse effects/*therapeutic use[MESH] |Hospitalization[MESH] |Humans[MESH] |Hyperuricemia/blood/etiology/*prevention & control[MESH] |Inflammation Mediators/blood[MESH] |Kaplan-Meier Estimate[MESH] |Kidney Diseases/blood/complications/*drug therapy/physiopathology[MESH] |Middle Aged[MESH] |Proportional Hazards Models[MESH] |Prospective Studies[MESH] |Risk Assessment[MESH] |Risk Factors[MESH] |Spain[MESH] |Time Factors[MESH] |Treatment Outcome[MESH]Effect of allopurinol in chronic kidney disease progression and cardio(epmc).pdf DeepDyve Pubget Overpricing